The 7-OH Kratom Ban: What Providers Need to Know About 7-Hydroxymitragynine Restrictions in Georgia and the Southeast

August 6, 2026

The 7-OH Kratom Ban: What Providers Need to Know About 7-Hydroxymitragynine Restrictions in Georgia and the Southeast

If you've been following emerging substance trends in your patient populations — particularly in addiction recovery and pain management — you've likely heard chatter about 7-Hydroxymitragynine, commonly called 7-OH. This concentrated kratom alkaloid has moved from gas-station shelves to legislative chambers at remarkable speed, and for good reason.

Let's break down what's happening, why it matters to your practice, and how your laboratory testing strategy needs to evolve.

What Is 7-Hydroxymitragynine (7-OH)?

Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Its leaves contain dozens of alkaloids, but two dominate the pharmacological conversation:

Mitragynine — the most abundant alkaloid (~66% of alkaloid content), which acts as a partial agonist at mu-opioid receptors
7-Hydroxymitragynine (7-OH) — present naturally in trace amounts (<2%), but roughly 13–46 times more potent than mitragynine at mu-opioid receptors

Here's the critical distinction: traditional kratom leaf products contain very low concentrations of 7-OH. The products now drawing regulatory scrutiny are concentrated extracts and synthetic formulations that dramatically amplify 7-OH content — sometimes to levels hundreds of times higher than what occurs naturally.

These concentrated 7-OH products are sold as shots, gummies, tablets, and powders, often marketed with names that downplay their opioid-like potency. They bind opioid receptors with enough affinity to produce euphoria, physical dependence, and withdrawal syndromes that clinically mirror traditional opioid use disorder.

Why Are Lawmakers and Health Officials Concerned?

The concern isn't theoretical. Emergency departments and addiction treatment programs across the Southeast have reported increasing presentations tied to concentrated 7-OH products, including:

Respiratory depression at high doses
Neonatal withdrawal syndromes in infants born to mothers using concentrated kratom extracts
Seizures in individuals combining 7-OH with other CNS depressants
Relapse masking — patients in recovery programs using 7-OH products that don't trigger standard immunoassay opioid screens

That last point deserves emphasis. For providers running addiction recovery and medication-assisted treatment (MAT) programs, 7-OH represents a significant blind spot in conventional drug testing — patients can maintain opioid receptor activation while appearing compliant on standard panels.

The Regulatory Landscape: Georgia and the Southeast

Georgia has been at the forefront of addressing this issue. Here's where things stand across the region:

Georgia

Georgia's Kratom Consumer Protection Act initially regulated kratom products but did not specifically address concentrated 7-OH extracts. Recent legislative action has moved to ban or severely restrict products containing 7-Hydroxymitragynine above naturally occurring concentrations. Synthetic 7-OH is now effectively prohibited from retail sale.

Neighboring States

Alabama — Kratom (including all alkaloids) has been classified as a Schedule I controlled substance since 2016
Tennessee — Enacted a Kratom Consumer Protection Act with specific concentration limits; synthetic 7-OH products face prohibition
Florida — Largely unregulated at the state level, though several counties have local restrictions; legislative momentum is building
Mississippi — Currently unregulated, though bills have been introduced
South Carolina — Consumer protection framework under consideration with attention to extract concentrations

The trend is clear: states are distinguishing between traditional kratom leaf and concentrated/synthetic 7-OH products, and the latter are facing bans or strict concentration caps.

Impact on Addiction Treatment Providers

For clinicians running recovery programs, these regulatory changes carry several practical implications:

Patients may not disclose 7-OH use — Many don't consider kratom products "drugs" because they're sold legally (or were until recently)
Standard immunoassay panels don't detect kratom alkaloids — You need specific testing to identify mitragynine and 7-OH metabolites
Withdrawal management — Patients discontinuing concentrated 7-OH may present with opioid-like withdrawal requiring clinical support
Program integrity — Without targeted testing, program outcomes data may be compromised by undetected opioid-receptor agonist use

Impact on Employers and Workplace Testing

Employers in safety-sensitive industries are starting to ask about kratom — particularly in transportation, manufacturing, and healthcare. While kratom isn't included in federal workplace testing panels (SAMHSA 5-panel or DOT), private employers in states banning 7-OH may have grounds to include kratom metabolite testing in their programs.

Providers advising employer clients should be prepared to discuss:

Whether state law now classifies 7-OH as a controlled substance (triggering MRO review processes)
Availability of confirmatory testing for kratom alkaloids
Turnaround time expectations for expanded panels

How Clinical Laboratories Are Adapting

The analytical challenge with kratom and 7-OH is real. Here's what modern laboratory response looks like:

LC-MS/MS confirmation — Liquid chromatography-tandem mass spectrometry can specifically identify and quantify mitragynine, 7-hydroxymitragynine, and their metabolites
Custom panel integration — Adding kratom analytes to existing toxicology panels without requiring a separate specimen or order
Reporting that maps to regulatory frameworks — As states set concentration thresholds, laboratories need to provide quantitative results, not just qualitative positive/negative calls
Rapid turnaround — In treatment settings, a 7-day result is clinically useless. Providers need results fast enough to inform real-time treatment decisions

At PillarsDx, we've integrated kratom alkaloid detection — including specific 7-OH identification — into our toxicology offerings. With 24-hour turnaround on most panels and concierge-level support, our team works directly with providers to configure panels that address emerging substances before they become compliance liabilities.

Frequently Asked Questions

Does a standard urine drug screen detect 7-OH or kratom?

No. Standard immunoassay panels (including expanded panels) do not cross-react reliably with mitragynine or 7-hydroxymitragynine. Specific LC-MS/MS testing is required.

Is kratom itself banned in Georgia?

Not entirely. Georgia regulates kratom under its Consumer Protection Act, but the recent restrictions specifically target concentrated and synthetic 7-OH products that exceed naturally occurring alkaloid ratios. Traditional kratom leaf products that comply with labeling and concentration standards remain available.

How should I talk to patients about 7-OH?

Providers should screen for kratom use during intake — particularly in addiction medicine and pain management settings. Many patients use kratom as self-medication for opioid withdrawal or chronic pain without understanding its opioid-receptor activity.

Can 7-OH cause physical dependence?

Yes. At the concentrations found in extract products, 7-OH produces clinically significant physical dependence. Withdrawal presentations include muscle aches, insomnia, irritability, nausea, and autonomic instability — closely paralleling opioid withdrawal.

How quickly can PillarsDx return kratom-specific results?

Most toxicology panels, including those with kratom alkaloid add-ons, are resulted within 24 hours of specimen receipt at our Alpharetta laboratory.

Should I add kratom testing to all patients or only suspected users?

This depends on your patient population and program requirements. For addiction treatment and MAT programs, we recommend routine inclusion given the prevalence of undisclosed use. For general pain management, risk-stratified ordering may be appropriate. Our clinical support team can help you design a panel strategy that balances clinical utility with cost.

Staying Ahead of Emerging Substance Trends

The 7-OH story is a textbook example of how quickly the substance landscape shifts — and how laboratory testing must evolve in lockstep with both clinical reality and regulatory frameworks.

PillarsDx was built for exactly this kind of challenge. Our approach combines:

Pharmacogenomic (PGx) testing to understand individual metabolic variation — relevant when patients are transitioning from kratom to evidence-based treatments
Comprehensive toxicology panels that go beyond standard analyte lists to include emerging substances like kratom alkaloids, synthetic cannabinoids, and novel psychoactive substances
Molecular diagnostics capabilities that allow rapid integration of new analytes as the regulatory environment evolves
24-hour turnaround that keeps pace with clinical decision-making
Dedicated concierge support — when a new state ban drops and you need to update your testing protocol, you won't be navigating a phone tree

The regulatory landscape around 7-OH is still evolving. States across the Southeast are actively drafting and amending legislation. Providers who establish robust testing protocols now — rather than reacting after a compliance issue or adverse patient outcome — position themselves as leaders in evidence-based, responsive care.

Need to update your toxicology panel to include kratom alkaloids? Want to discuss how PGx insights can support patients transitioning off kratom products? Reach out to the PillarsDx clinical team — we're here to help you navigate the complexity.